NovoCure Limited (NVCR) Guidance & Earnings Results
On 2026-07-23 NovoCure Limited raised guidance: "FY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVCRNovoCure LimitedFollow NVCR — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 23 Jul 26 | Raised | FY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance $20M-$30M · full year |
| 30 Apr 26 | Raised | Total net revenue $690-710M; Adjusted EBITDA $(15)-$0M · full year |
NovoCure Limited — questions
- What guidance did NovoCure Limited give?
- On 2026-07-23: "FY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance $20M-$30M"
- When does NovoCure Limited report earnings?
- NovoCure Limited's next earnings report is expected on 2026-10-29.
Every figure on this page comes from NovoCure Limited's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.